Evidence map›Paper›PMID 36175500›Full record

ArticleScientific reports2022

Induction of ROS mediated genomic instability, apoptosis and G0/G1 cell cycle arrest by erbium oxide nanoparticles in human hepatic Hep-G2 cancer cells.

Gehan Safwat, Esraa S M Soliman, Hanan R H Mohamed

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. YScientific reports · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Pluronic-F-127-Passivated SnOPlants (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Gehan SafwatFaculty of Biotechnology, October University for Modern Sciences and Arts, 6th of October, Egypt.
Esraa S M SolimanFaculty of Biotechnology, October University for Modern Sciences and Arts, 6th of October, Egypt.
Hanan R H MohamedZoology Department, Faculty of Science, Cairo University, Giza, Egypt. hananeeyra@cu.edu.eg.
October University of Modern Sciences and Arts · EGCairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The remarkable physical and chemical characteristics of noble metal nanoparticles, such as high surface-to-volume ratio, broad optical properties, ease of assembly, surfactant and functional chemistry, have increased scientific interest in using erbium oxide nanoparticles (Er

Indexed as

Liver NeoplasmsMetal NanoparticlesApoptosisbcl-2-Associated X ProteinCell Line, TumorErbiumG1 Phase Cell Cycle CheckpointsGenomic InstabilityHumansOxidesReactive Oxygen SpeciesSurface-Active AgentsTumor Suppressor Protein p53bcl-2-Associated X ProteinErbiumerbium oxideOxidesReactive Oxygen SpeciesSurface-Active AgentsTumor Suppressor Protein p53

Identifiers

PMID36175500
PMCPMC9522848
OpenAlexW4298006459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.